Browse by Subject
- Administrative Sciences
- Biochemistry, Medicine & Health
- Computer & Communication Sciences
- Environmental Sciences
- Geographic Information Science
IOS Press publishes books and journals (online and in print) in a broad range of scientific, technical and medical (STM) subject areas. Click on a subject above to see our titles.
NewsKeep me informed
December 12, 2013 - On 1 January 2014 ACCUCOMS will take over from Van De Bilt Sales and Marketing in representing IOS Press across the whole of Europe and Turkey.
December 3, 2013 - At the first signs of memory loss, most people start worrying and wonder, “What if I have Alzheimer's disease?” And yet, the disease is often diagnosed late in its development and sometimes up to ten years after the first pathological changes have affected the brain. A major goal in the treatment of Alzheimer's disease has been to provide earlier diagnosis so that patients can receive treatment as early as possible. A study by Sylvie Belleville, PhD, Director of Research at the Institut universitaire de gériatrie de Montréal, an institution affiliated with Université de Montréal, has shown a way to do just that. In their study, Sylvie Belleville and her team accurately predicted (at a rate of 90%) which of their research subjects with mild cognitive impairment would receive a clinical diagnosis of Alzheimer's disease within the following two years and which subjects would not develop this disease. The study was published in Volume 38, Issue 2 of the prestigious Journal of Alzheimer's Disease.
November 20, 2013 - Nonarteritic anterior ischemic optic neuropathy (NAION) is one of the leading causes of sudden and irreversible loss of vision in older adults. In a prospective randomized trial of 60 patients with NAION, investigators have shown that the addition of the corticosteroid fluocortolone (FC) to standard therapy significantly improves both short- and long-term visual acuity, especially when given soon after the onset of symptoms. Their results are published in Restorative Neurology and Neuroscience.
Prescription of anti-Alzheimer medications to persons with mild cognitive impairment (MCI) is low in France
November 15, 2013 - In France prescription of drugs for Alzheimer’s disease (AD) is strictly regulated. The Department of Public Health and the Memory Clinic of Nice University Hospital have explored real world prescriptions of anti-AD medications in patients with mild cognitive impairment (MCI) not AD. A national survey  was set up from the data of the French National Alzheimer Databank (BNA) and shows that off label prescriptions are not frequent and concern 6.1% of MCI patients (versus a quarter of MCI patients in the US ). French physicians seem to limit this kind of prescription to MCI patients at risk of conversion to AD: more aged, with a more important quantitative cognitive impairment and with a memory predominant form. In a context of low efficacy of the available medications against AD this study emphasizes the need to develop more preventive drugs.
IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.